Novartis (Sweden)-ko ikertzaileekin lankidetzan egindako argitalpenak (11)

2024

  1. A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies

    OncoImmunology, Vol. 13, Núm. 1

  2. Unmet clinical needs, burden of disease and treatment patterns in hidradenitis suppurativa: Real-world experience from Spain

    JEADV Clinical Practice, Vol. 3, Núm. 1, pp. 347-357

2023

  1. International Hidradenitis Suppurativa Severity Scoring System (IHS4) as a holistic measure of hidradenitis suppurativa disease severity compared with Hurley staging: A post hoc analysis of the SUNRISE and SUNSHINE phase 3 trials of secukinumab

    Journal of the European Academy of Dermatology and Venereology

2020

  1. COPD clinical control as a predictor of future exacerbations: Concept validation in the SPARK study population

    Thorax, Vol. 75, Núm. 4, pp. 351-353

2019

  1. Safety of everolimus with reduced calcineurin inhibitor exposure in de novo kidney transplants: An analysis from the randomized transform study

    Transplantation, Vol. 103, Núm. 9, pp. 1953-1963

2003

  1. Aminopeptidase activity in renovascular hypertension

    Medical Science Monitor, Vol. 9, Núm. 1

  2. Angiotensinase activities in the kidney of renovascular hypertensive rats

    Peptides, Vol. 24, Núm. 5, pp. 755-760

  3. Angiotensinase activity in hypothalamus and pituitary of hypothyroid, euthyroid and hyperthyroid adult male rats

    Hormone and Metabolic Research, Vol. 35, Núm. 5, pp. 279-281

2001

  1. Aminopeptidase activities after water deprivation in male and female rats

    Regulatory Peptides, Vol. 101, Núm. 1-3, pp. 189-194

  2. Effect of valsartan on angiotensin II- and vasopressin-degrading activities in the kidney of normotensive and hypertensive rats

    Hormone and Metabolic Research, Vol. 33, Núm. 9, pp. 559-563

2000

  1. Oral administration of losartan influences aminopeptidase activity in the frontal cortex

    European Neuropsychopharmacology, Vol. 10, Núm. 4, pp. 279-282